These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16831969)

  • 1. At risk for Huntington disease: The PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled.
    Huntington Study Group PHAROS Investigators
    Arch Neurol; 2006 Jul; 63(7):991-6. PubMed ID: 16831969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.
    ; Biglan KM; Shoulson I; Kieburtz K; Oakes D; Kayson E; Shinaman MA; Zhao H; Romer M; Young A; Hersch S; Penney J; Marder K; Paulsen J; Quaid K; Siemers E; Tanner C; Mallonee W; Suter G; Dubinsky R; Gray C; Nance M; Bundlie S; Radtke D; Kostyk S; Baic C; Caress J; Walker F; Hunt V; O'Neill C; Chouinard S; Factor S; Greenamyre T; Wood-Siverio C; Corey-Bloom J; Song D; Peavy G; Moskowitz C; Wesson M; Samii A; Bird T; Lipe H; Blindauer K; Marshall F; Zimmerman C; Goldstein J; Rosas D; Novak P; Caviness J; Adler C; Duffy A; Wheelock V; Tempkin T; Richman D; Seeberger L; Albin R; Chou KL; Racette B; Perlmutter JS; Perlman S; Bordelon Y; Martin W; Wieler M; Leavitt B; Raymond L; Decolongon J; Clarke L; Jankovic J; Hunter C; Hauser RA; Sanchez-Ramos J; Furtado S; Suchowersky O; Klimek ML; Guttman M; Sethna R; Feigin A; Cox M; Shannon B; Percy A; Dure L; Harrison M; Johnson W; Higgins D; Molho E; Nickerson C; Evans S; Hobson D; Singer C; Galvez-Jimenez N; Shannon K; Comella C; Ross C; Saint-Hilaire MH; Testa C; Rosenblatt A; Hogarth P; Weiner W; Como P; Kumar R; Cotto C; Stout J; Brocht A; Watts A; Eberly S; Weaver C; Foroud T; Gusella J; MacDonald M; Myers R; Fahn S; Shults C
    JAMA Neurol; 2016 Jan; 73(1):102-10. PubMed ID: 26569098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotype-genotype discrepancies in the prospective Huntington at-risk observational study.
    Shoulson I; Eberly S; Oakes D; Kayson E; Young AB;
    Ann Clin Transl Neurol; 2019 Jun; 6(6):1046-1052. PubMed ID: 31211168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive changes in asymptomatic carriers of the Huntington disease mutation gene.
    Verny C; Allain P; Prudean A; Malinge MC; Gohier B; Scherer C; Bonneau D; Dubas F; Le Gall D
    Eur J Neurol; 2007 Dec; 14(12):1344-50. PubMed ID: 17941857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [From gene to disease; HD gene and Huntington disease].
    Maat-Kievit JA; Losekoot M; Roos RA
    Ned Tijdschr Geneeskd; 2001 Nov; 145(44):2120-3. PubMed ID: 11723754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between BDNF Val66Met polymorphism and age at onset in Huntington disease.
    Alberch J; López M; Badenas C; Carrasco JL; Milà M; Muñoz E; Canals JM
    Neurology; 2005 Sep; 65(6):964-5. PubMed ID: 16186551
    [No Abstract]   [Full Text] [Related]  

  • 7. Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study.
    ; Dorsey E
    PLoS One; 2012; 7(2):e29522. PubMed ID: 22359536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Juvenile Huntington disease in Argentina.
    Gatto EM; Parisi V; Etcheverry JL; Sanguinetti A; Cordi L; Binelli A; Persi G; Squitieri F
    Arq Neuropsiquiatr; 2016 Jan; 74(1):50-4. PubMed ID: 26602194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the correlates of intermediate CAG repeats in Huntington disease.
    Ha AD; Jankovic J
    Postgrad Med; 2011 Sep; 123(5):116-21. PubMed ID: 21904093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Informativeness of Early Huntington Disease Signs about Gene Status.
    Oster E; Eberly SW; Dorsey ER; Kayson-Rubin E; Oakes D; Shoulson I
    J Huntingtons Dis; 2015; 4(3):271-7. PubMed ID: 26444024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
    Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
    Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
    Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
    Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left by the lakeside.
    Ceaser M
    Lancet; 2004 Aug 14-20; 364(9434):569-70. PubMed ID: 15314834
    [No Abstract]   [Full Text] [Related]  

  • 14. Uptake of Huntington disease predictive testing in a complete population.
    Morrison PJ; Harding-Lester S; Bradley A
    Clin Genet; 2011 Sep; 80(3):281-6. PubMed ID: 20880124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prospective Huntington At-Risk Observational Study (PHAROS): The Emotional Well-Being, Safety and Feasibility of Long-Term Research Participation.
    Kayson E; Eberly S; Anderson KE; Marder K; Shoulson I; Oakes D; Young AB; Biglan K; Hersch S;
    J Huntingtons Dis; 2019; 8(4):435-441. PubMed ID: 31381523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of meiotic variability of the (CAG)n repeat in the Huntington disease gene.
    Lucotte G; Gérard N; Aouizérate A; Loirat F; Hazout S
    Genet Couns; 1997; 8(2):77-81. PubMed ID: 9219003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are cognitive changes progressive in prediagnostic HD?
    Stout JC; Weaver M; Solomon AC; Queller S; Hui S; Johnson SA; Gray J; Beristain X; Wojcieszek J; Foroud T
    Cogn Behav Neurol; 2007 Dec; 20(4):212-8. PubMed ID: 18091069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychomotor, executive, and memory function in preclinical Huntington's disease.
    Snowden JS; Craufurd D; Thompson J; Neary D
    J Clin Exp Neuropsychol; 2002 Apr; 24(2):133-45. PubMed ID: 11992196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ancient origin of the CAG expansion causing Huntington disease in a Spanish population.
    García-Planells J; Burguera JA; Solís P; Millán JM; Ginestar D; Palau F; Espinós C
    Hum Mutat; 2005 May; 25(5):453-9. PubMed ID: 15832309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease.
    Petrasch-Parwez E; Nguyen HP; Löbbecke-Schumacher M; Habbes HW; Wieczorek S; Riess O; Andres KH; Dermietzel R; Von Hörsten S
    J Comp Neurol; 2007 Apr; 501(5):716-30. PubMed ID: 17299753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.